论文部分内容阅读
目的探究丹参川芎嗪治疗患者缺血性心肌病的临床疗效。方法将120例符合缺血性心肌病诊断标准的患者随机分成对照组和治疗组,两组常规给予药物治疗,包括受体阻滞剂、血管紧张素转换酶抑制剂、洋地黄和醛固酮受体拮抗剂等药物治疗,治疗组加用丹参川芎嗪,12周后观察两组心脏彩超LVEF值及心功能、心电图的变化。结果两组治疗后心脏彩超LVEF、心电图改善比较差异有统计学意义(P<0.01),但心功能的改善比较差异未见统计学意义(P>0.05)。结论治疗患者,在应用药物治疗基础上加用丹参川芎嗪治疗缺血性心肌病能显著改善患者的临床症状,提高患者的生活质量。
Objective To investigate the clinical efficacy of ligustrazine injection in the treatment of ischemic cardiomyopathy. Methods One hundred and twenty patients with diagnostic criteria of ischemic cardiomyopathy were randomly divided into control group and treatment group. The two groups were routinely given drug therapy, including receptor blockers, angiotensin converting enzyme inhibitors, digitalis and aldosterone receptor Antagonists and other drugs, the treatment group with Salvia Ligustrazine, 12 weeks after the two groups were observed LVEF value of cardiac ultrasonography and cardiac function, ECG changes. Results After treatment, LVEF and ECG of two groups had significant difference (P <0.01). However, there was no significant difference between the two groups in the improvement of cardiac function (P> 0.05). Conclusion In the treatment of patients, the application of Salviae miltiorrhizae ligustrazine in the treatment of ischemic cardiomyopathy can significantly improve the clinical symptoms and improve the quality of life of patients.